Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
Kloner
Robert A
RA
Heart Institute, Good Samaritan Hospital, Los Angeles, CA, USA.
Montorsi
Piero
P
DeBusk
Robert F
RF
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000453:epidemiology* / Q000503:physiopathology; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000453:epidemiology*; D006801:Humans; D008297:Male; D009574:Nitro Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D012720:Severity of Illness Index; D028761:Withholding Treatment
D009574:Nitro Compounds; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human